Sugi Predict

Sugi Predict / Compounds / SCHEMBL6842544

SCHEMBL6842544

SCHEMBL6842544

CCC(C)(C)c1ccc(N(CCO)CCO)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.40
▸ RAB9A P51151 4/20 0.40
▸ MAPT P10636 3/20 0.40
▸ CNR2 P34972 3/20 0.37
▸ NR1H2 P55055 5/20 0.36
▸ NR1H3 Q13133 5/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ SENP8 Q96LD8 1/20 0.34
▸ SENP7 Q9BQF6 1/20 0.34
▸ SENP6 Q9GZR1 1/20 0.34
▸ SLC29A1 Q99808 1/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ MLYCD O95822 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11589961 0.83 ALDH1A1 (0.39) NPC1RAB9AMAPTNR1H2NR1H3
SCHEMBL44011 0.82 LMNA (0.43) NPC1RAB9AMAPTSMN1; SMN2MAPK1
SCHEMBL12601922 0.78 NR1H2 (0.43) NPC1RAB9AMAPTCNR2NR1H2
SCHEMBL7921715 0.77 SMN1; SMN2 (0.36) NPC1RAB9AMAPTNR1H2NR1H3
SCHEMBL23172938 0.77 NR1H2 (0.36) NPC1RAB9AMAPTCNR2NR1H2
SCHEMBL6243535 0.77 MAPT (0.44) NPC1RAB9AMAPTSMN1; SMN2MAPK1
SCHEMBL10485747 0.76 ALDH1A1 (0.54) NPC1RAB9AMAPTCNR2MAPK1
SCHEMBL2006984 0.75 KMT2A (0.41) NPC1RAB9AMAPTSMN1; SMN2MAPK1
Hydrochloric Acid SCHEMBL8038931 0.75 MAPT (0.43) NPC1RAB9AMAPTSMN1; SMN2MAPK1
SCHEMBL779443 0.74 NPC1 (0.58) NPC1RAB9AMAPTCNR2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6765117-B2 PREPARING 9-DEOXY-PGF1-TYPE COMPOUNDS, LESS STEPS; CYCLIZATION OF AN INTERMEDIATE COMPRISING A BENZENE SUBSTITUTED WITH A TRIPLE BOND AND A DOUBLE BOND UNITED THERAPEUTIC CORPORATION 2004-07-20 — — US disclosed
US-20030083381-A1 Hair growth or hair formation controlling agents TORAY INDUSTRIES, INC. (JP) 2003-05-01 — — US disclosed
US-6555559-B1 Prostaglandin I2 (PGI2); use as an anti-Helicobacter agent, a platelet function potentiating agent or a cervical ripening agent; side effect reduction TORAY INDUSTRIES, INC. (JP) 2003-04-29 — — US disclosed
EP-1186287-A1 HAIR GROWTH OR HAIR FORMATION CONTROLLING AGENTS TORAY INDUSTRIES, INC. (JP) 2002-03-13 — — EP disclosed
EP-1044972-A1 5,6,7-TRINOR-4,8-INTER-m-PHENYLENE PGI2 DERIVATIVE AND DRUGS CONTAINING THE SAME TORAY INDUSTRIES, INC. (JP) 2000-10-18 — — EP disclosed
US-5401768-A Prostaglandin derivative, antiulcer, hypotensive, anticoagulant TORAY INDUSTRIES, INC. (JP) 1995-03-28 — — US disclosed
EP-0339046-B1 LEUKOTRIENE B 4 ANALOGS UPJOHN CO (US) 1995-02-15 — — EP disclosed
EP-0084856-B2 5,6,7-Trinor-4, 8-inter-m-phenylene prostaglandin I2 derivatives TORAY INDUSTRIES (JP) 1994-05-04 — — EP disclosed
EP-0365678-B1 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF TORAY INDUSTRIES (JP) 1994-01-05 — — EP disclosed
US-5116981-A Antiinflammatory leukotriene B4 analogs THE UPJOHN COMPANY (US) 1992-05-26 — — US disclosed
US-3933900-A ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING THE UPJOHN COMPANY (US) 1976-01-20 — — US disclosed
US-3933899-A ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING THE UPJOHN COMPANY (US) 1976-01-20 — — US disclosed
US-3933898-A ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING THE UPJOHN COMPANY (US) 1976-01-20 — — US disclosed
US-3933897-A ANTIULCER, ASTHMA, RENAL DYSFUNCTION THE UPJOHN COMPANY (US) 1976-01-20 — — US disclosed
US-3933889-A 4,5-Cis-didehydro-PGF1.sub.α analogs THE UPJOHN COMPANY (US) 1976-01-20 — — US disclosed
US-3932389-A ANTIULCER AGENTS PFIZER INC. (US) 1976-01-13 — — US disclosed
US-3931284-A 11β-PGE2 compounds THE UPJOHN COMPANY (US) 1976-01-06 — — US disclosed
US-3931283-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-01-06 — — US disclosed
US-3931289-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-01-06 — — US disclosed
US-3931279-A 5-Oxa prostaglandin F2.sub.α analogs THE UPJOHN COMPANY (US) 1976-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083381-A1 Hair growth or hair formation controlling agents PTGFR, PTGS1, PTGDR NPC1 4819/4885RAB9A 4634/4885MAPT 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.